Mourez Thomas, Delaugerre Constance, Vray Muriel, Lemée Véronique, Simon François, Plantier Jean-Christophe
Normandie Université, France; Université de Rouen, Institut de Recherche et d'Innovation Biomédicale (IRIB), Equipe d'Accueil 2656, F-76183 Rouen, France; CHU de Rouen, Laboratoire de Virologie Associé au Centre National de Référence du VIH, F-76031 Rouen, France.
Université Denis Diderot Paris 7, F-75010 Paris, France; AP-HP, hôpital Saint-Louis, Laboratoire de Virologie, F-75010 Paris, France.
J Clin Virol. 2015 Oct;71:76-81. doi: 10.1016/j.jcv.2015.08.007. Epub 2015 Aug 18.
An improved version of the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 has been introduced to overcome the underquantification observed with previous versions, especially with non-B HIV-1 subtypes.
Comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 versus Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays for HIV-1 group M and non-M (N, O, P) viral load measurement.
The three assays were tested in parallel on 103HIV-1 group M plasma samples, and on non-group M HIV-1 culture supernatants.
Values obtained for the 103HIV-1 group M plasma samples tested with bioMérieux assay showed good overall correlation compared to the 2 others. The Roche Cobas assay gave higher values than the bioMérieux assay, while Abbott and bioMérieux both displayed similar results. However, analysis showed a wider dispersion in results when comparing the bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques. All data taken into account, we observed frequent discrepancies in quantification, of the plasma samples and major differences above 1log in 10/72 (13.8%). The quantification of non-M HIV groups in culture supernatant has shown variable results, with better quantification of HIV-O and of HIV-N respectively with the Abbott assay and the bioMérieux assay.
The bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 showed improved sensitivity to non-B HIV-M subtypes compared to previous versions. Notwithstanding, we observed frequent discrepancies and a wide dispersion in results when comparing bioMérieux NucliSENS(®) EasyQ(®) HIV-1 v2.0 and the other 2 techniques.
生物梅里埃公司的NucliSENS(®) EasyQ(®) HIV-1 v2.0改进版已推出，以克服先前版本存在的定量不足问题，尤其是对非B型HIV-1亚型的定量不足。
比较生物梅里埃公司的NucliSENS(®) EasyQ(®) HIV-1 v2.0与罗氏Cobas CA/CTM v2.0以及雅培实时HIV-1检测法对HIV-1 M组和非M组（N、O、P）病毒载量的测定。
对103份HIV-1 M组血浆样本以及非M组HIV-1培养上清液同时进行这三种检测。
与其他两种检测法相比，用生物梅里埃检测法检测103份HIV-1 M组血浆样本所获得的值总体相关性良好。罗氏Cobas检测法得到的值高于生物梅里埃检测法，而雅培和生物梅里埃检测法的结果相似。然而，分析表明，在比较生物梅里埃公司的NucliSENS(®) EasyQ(®) HIV-1 v2.0与其他两种技术时，结果的离散度更大。综合所有数据，我们观察到血浆样本定量中频繁出现差异，在10/72（13.8%）的样本中差异超过1个对数。培养上清液中非M型HIV组的定量结果各不相同，雅培检测法对HIV-O的定量效果较好，生物梅里埃检测法对HIV-N的定量效果较好。
与先前版本相比，生物梅里埃公司的NucliSENS(®) EasyQ(®) HIV-1 v2.0对非B型HIV-M亚型的敏感性有所提高。尽管如此，在比较生物梅里埃公司的NucliSENS(®) EasyQ(®) HIV-1 v2.0与其他两种技术时，我们观察到结果频繁出现差异且离散度较大。
